Lexaria Bioscience Corp. (LEXX)
Market Cap | 39.43M |
Revenue (ttm) | 385,995 |
Net Income (ttm) | -5.45M |
Shares Out | 12.89M |
EPS (ttm) | -0.68 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 119,386 |
Open | 3.180 |
Previous Close | 3.150 |
Day's Range | 3.050 - 3.200 |
52-Week Range | 0.649 - 6.850 |
Beta | 0.98 |
Analysts | Strong Buy |
Price Target | 12.00 (+292.16%) |
Earnings Date | Jul 12, 2024 |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain ... [Read more]
Financial Performance
In 2023, LEXX's revenue was $226,208, a decrease of -11.43% compared to the previous year's $255,397. Losses were -$6.66 million, -8.31% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LEXX stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? KELOWNA, BC / ACCESSWIRE / May 17,...
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
KELOWNA, BC / ACCESSWIRE / May 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot stu...
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
KELOWNA, BC / ACCESSWIRE / May 6, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research ...
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has entered in...
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Human Pilot Study #2 (GLP-1-H24-2) Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug de...
Lexaria Awarded New Patents
Lexaria receives new patents in the fields of epilepsy and anti-viral agents KELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"...
Lexaria to Present at The LD Micro Invitational XIV
Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms annou...
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment o...
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be tested Rybelsus ® semaglutide will act as the positive control KELOWNA, BC / ACCESSWIRE / March 7, 2024 / Lexaria Bioscience Corp. ...
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested Chronic dosing over a 12-week treatment period Will assess weight loss and blood glucose level control Efficacy through possibl...
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study
KELOWNA, BC / ACCESSWIRE / March 4, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, informs that its wholly-own...
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
KELOWNA, BC / ACCESSWIRE / March 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the U.S. Foo...
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / February 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq;LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / February 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...
Lexaria's Submits Investigational New Drug Application
KELOWNA, BC / ACCESSWIRE / January 30, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that, on January 29, ...
Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESSWIRE / January 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX),(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide th...
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
Extensive work program designed to support commercial discussions. KELOWNA, BC / ACCESSWIRE / January 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabete...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ br...
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
Final results from a human pilot study show DehydraTECHTM-powered semaglutide outperforms Rybelsus®: Sustained higher levels of semaglutide in blood; Better blood glucose control; Faster achievement o...
Lexaria's Investigational New Drug Application Filing Update
KELOWNA, BC / ACCESSWIRE / December 7, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Compa...
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hour...
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study
DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus ® : Sustained higher levels of semaglutide in blood; Faster achievement of peak drug delivery; and...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ br...
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded Minimum ongoing payments, royalties and manufacturing revenues part of the agreement KELOWNA, BC...